Is it time to treat prehypertension?

Hypertension Research

Volumn 31, Issue 9, 2008, Pages 1681-1686

  Papadopoulos, Dimitris P ^a   Makris, Thomas K ^a   Papademetriou, Vasilios ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blocker; Candesartan; Hypertension; Prehypertension; Trial of Preventing Hypertension (TROPHY) study

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL; PLACEBO;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PREHYPERTENSION; PREVALENCE; PROGNOSIS; PUBLIC HEALTH; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 55449092891     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1681     Document Type: Review

References (42)

1. Chobanian AV, Bakris GL, Black HR, et al: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. Hypertension 2003; 42: 1206-1252.
2. Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
3. Julius S, Jamerson K, Mejia A, et al: The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA 1990; 264: 354-358.
4. Vasan RS, Larson MG, Leip EP, et al: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
5. Neaton JD, Kuller L, Stamler J, Wentworth DN: Impact of systolic and diastolic blood pressure on cardiovascular mortality. in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York, Raven Press, 1995, pp 127-144.
6. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J: Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158: 2007-2014.
7. Greenlund KJ, Croft JB, Mensah GA: Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Int Med 2004; 164: 2113-2118.
8. Chobanian AV: Prehypertension revisited. Hypertension 2006; 48: 812-814.
9. Vasan RS, Beiser A, Seshadri S, et al: Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287: 1003-1010.
10. Mainous AG, Everett CJ, Liszka H, King DE, Egan BM: Prehypertension and mortality in a nationally representative cohort. Am J Cardiol 2004; 94: 1496-1500.
11. Okosun IS, Boltri JM, Anochie LK, Chandra KMD: Racial/ethnic differences in prehypertension in American adults: population and relative attributable risk of abdominal obesity. J Hum Hypertens 2004; 18: 849-855.
12. Tsai P-S, Ke T-L, Huang C-J, et al: Prevalence and determinants of prehypertension status in the Taiwanese general population. J Hypertens 2005; 223: 1355-1360.
13. Cordero A, Laclaustra M, Leon M, et al: Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. Am J Hypertens 2006; 19: 189-196.
14. Zhang Y, Lee ET, Devereux RB, et al: Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 2006; 47: 410-414.
15. Lee JE, Kim Y-G, Choi Y-H, Huh W, Kim DJ, Oh HY: Serum uric acid is associated with microalbuminuria in pre-hypertension. Hypertension 2006; 47: 962-967.
16. King DE, Egan BM, Mainous AG, Geesey ME: Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens 2004; 6: 562-568.
17. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C: Association between prehypertension status and inflammatory markers related to atherosclerotic disease. The ATTICA Study. Am J Hypertens 2004; 17: 568-573.
18. Papadopoulos DP, Makris TK, Krespi PG, et al: Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J Clin Hypertens 2005; 7: 729-733.
19. Toikka JO, Laine H, Ahotupa M, et al: Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 2000; 36: 929-933.
20. Washio M, Tokunaga S, Yoshimasu K, et al: Role of prehypertension in the development of coronary atherosclerosis in Japan. J Epidemiol 2004; 14: 57-62.
21. Erdogan D, Caliskan M, Yildirim I, et al: Effects of normal blood pressure, prehypertension and hypertension on left ventricular diastolic function and aortic elastic properties. Blood Press 2007; 16: 114-121.
22. Liszka HA, Mainous AG, King DE, Everett CJ, Egan BM: Prehypertension and cardiovascular morbidity. Ann Fam Med 2005; 3: 294-299.
23. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE: Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 199: 133-141.
24. Qureshi AI, Suri FK, Kirmani JF, Divani AA, Mohammed Y: Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005; 36: 1859-1863.
25. Fox KM, European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
26. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
27. Patel A, MacMahon S, Chalmers J, et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
28. Harada K, Karube Y, Saruhara H, Takeda K, Kuwajima I: Workplace hypertension is associated with obesity and family history of hypertension. Hypertens Res 2006; 29: 969-976.
29. Light KC, Turner JR, Hinderliter AL: Job strain and ambulatory work blood pressure in healthy young men and women. Hypertension 1992; 20: 214-218.
30. Fiedler N, Favata E, Goldstein BD, Gochfeld M: Utility of occupational blood pressure screening for the detection of potential hypertension. J Occup Med 1988; 30: 943-948.
31. Schnall PL, Schwartz JE, Landsbergis PA, Warren K, Pickering TG: Relation between job strain, alcoholic, and ambulatory blood pressure. Hypertension 1992; 19: 488-494.
32. James GD, Pickering TG, Yee LS, Harshfield GA, Riva S, Laragh JH: The reproducibility of average ambulatory, home, and clinic pressures. Hypertension 1988; 11: 545-549.
33. Sacks FM, Svetkey LP, Vollmer WM, et al, DASH-Sodium Collaborative Research Group: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10.
34. Appel LJ, Sacks FM, Carey VJ, et al, OmniHeart Collaborative Research Group: Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005; 294: 2455-2464.
35. Appel LJ, Champagne CM, Harsha DW, et al, Writing Group of the PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289: 2083-2209.
36. Elmer PJ, Obarzanek E, Vollmer WM, et al, PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Int Med 2006; 144: 485-495.
37. Julius S, Nesbitt S, Egan B, et al, TROPHY Study Group: Trial of preventing hypertension: design and 2-year progress report. Hypertension 2004; 44: 146-151.
38. Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M: Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study. Am J Hypertens 2005; 18: 980-985.
39. Julius S, Nesbitt SD, Egan BM, et al: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
40. Julius S: Should the results of TROPHY affect the JNC 7 definition of prehypertension? Curr Hypertens Rep 2007; 9: 202-205.
41. Kjeldsen SE, Narkiewicz K, Hedner T: An American TROPHY in the prevention of hypertension. Blood Press 2006; 15: 132-134.
42. Suri MF, Qureshi AI: Prehypertension as a risk factor for cardiovascular diseases. J Cardiovasc Nurs 2006; 21: 478-484.